Table of contents
- Trial overview
- Who is being studied
- What the study tests
- Phase and study size
- Main outcomes and safety checks
- What the status means
Trial overview
The available clinical trial for IMMUNOSTEM is a first-in-human study in people with early type 1 diabetes.[1] It is an interventional trial, which means researchers are giving a treatment and then measuring what happens.[1]
The trial title says it is testing a gene therapy using the patient’s own stem cells to treat early type 1 diabetes.[1] The study brief summary says the main objective is to evaluate study treatment safety.[1]
Who is being studied
The condition being studied is type 1 diabetes, specifically early disease.[1] This means the trial is aimed at people who are in the early stage of this condition, not the general population.[1]
The planned enrollment is 15 patients, so this is a small early trial.[1] Small studies like this are common when a treatment is being tested for the first time in people.[1]
What the study tests
The intervention is described as autologous CD34+ HSPCs transduced ex vivo with a LVV encoding the hPD-L1 cDNA, given by intravenous use.[1] In simple words, the study uses the patient’s own stem cells, changes them in a laboratory, and gives them back through a vein.[1]
This article does not go beyond the trial data to explain how the treatment works, because the source information focuses on the study design and safety goals.[1]
Phase and study size
The trial is in phase 1/2.[1] Phase 1 studies usually look first at safety, while phase 2 studies look more closely at early signs of whether a treatment may be worth testing further.[1]
The study is authorised and has a planned enrollment of 15 patients.[1] This suggests an early development program with careful monitoring.[1]
Main outcomes and safety checks
The primary endpoint is safety.[1] The trial will measure the number and description of adverse events, which are unwanted medical problems that happen during the study.[1]
Safety will also be checked using vital signs, laboratory tests, and the frequency and severity of adverse events and serious adverse events.[1] Serious adverse events are more severe problems, such as those that are life-threatening or need hospital care.[1]
Safety will be assessed over the first 3, 12, and 24 months of follow-up in the pilot phase.[1] The data safety monitoring board, or DSMB, will review the pilot safety results at 3 months before the study can continue to the next stage.[1]
What the status means
The trial status is Authorised.[1] This means the study has been approved to move forward, but the source data do not show final results yet.[1]
Because this is an early trial, the main question is whether the treatment can be given safely to people with early type 1 diabetes.[1] The trial is not presented in the source as a completed study, so there are no outcome results to report yet.[1]
